CD274 and neoplasm: At present, it is believed that PD‐L1 may serve as a biomarker of potential clinical benefits, but not all tumors with high expression of PD‐L1 have a significant response to a PD‐L1/PD‐1 inhibitor, and some tumor patients with PD‐L1‐negative tumors can still have a significant response to a PD‐L1/PD‐1 inhibitor.13, 14